<DOC>
	<DOCNO>NCT01901146</DOCNO>
	<brief_summary>The purpose research study compare effectiveness safety ABP 980 trastuzumab woman early breast cancer .</brief_summary>
	<brief_title>Efficacy Safety Study ABP 980 Compared With Trastuzumab Subjects With HER2 Positive Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Females ≥ 18 year age Histologically confirm invasive breast cancer Planning surgical resection breast tumor sentinel node axillary lymph node resection Planning neoadjuvant chemotherapy HER2 positive disease Measurable disease breast diagnostic biopsy , define long diameter ≥ 2.0 cm Known Estrogen Receptor ( ER ) Progesterone Receptor ( PR ) hormone receptor status study entry Normal bone marrow function Normal hepatic function Normal renal function Subjects must sign Institutional Review Board/Ethics Committee ( IRB/EC ) approve informed consent form study specific procedure Inclusion Criteria Randomization : Left ventricular ejection fraction ( LVEF ) ≥55 % 2D echocardiogram Complete 4 cycle runin chemotherapy Bilateral breast cancer Presence know metastasis Received prior treatment , include chemotherapy , biologic therapy , radiation surgery exception diagnostic biopsy primary breast cancer Other concomitant active malignancy history malignancy past 5 year except treat basal cell carcinoma skin carcinoma situ cervix Preexisting clinically significant ( ≥ grade 2 ) peripheral neuropathy Any history document current congestive heart failure , current highrisk uncontrolled arrhythmias , current angina pectoris require medicinal product , current clinically significant valvular disease , current evidence transmural infarction electrocardiogram ( ECG ) , current poorly control hypertension Severe dyspnea rest require supplementary oxygen therapy History positivity hepatitis B surface antigen , hepatitis C virus , HIV Recent infection require course systemic antiinfectives complete ≤ 14 day enrollment ( exception uncomplicated urinary tract infection ) Woman childbearing potential pregnant breast feed Woman childbearing potential consenting use highly effective method birth control ( eg , true abstinence [ periodic abstinence ( eg calendar ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception ] , sterilization , nonhormonal form contraception ) treatment least 7 month last administration protocol specified treatment Currently receive treatment another investigational device drug study , less 30 day since end treatment another investigational device drug study Other investigational procedure participate study exclude Subject know sensitivity product administer study , include mammalian cell derive drug product , trastuzumab , murine protein , excipients Subject previously enrol and/or randomize study Subject likely available complete protocol require study visit procedure History evidence clinically significant disorder , condition disease ( exception outline ) , opinion Investigator Amgen physician , consult , would pose risk subject safety interfere study evaluation , procedure completion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Human Epidermal Growth Factor Receptor 2 ( HER2 )</keyword>
	<keyword>Positive Early Breast Cancer</keyword>
</DOC>